TRADE REMEDIES | 2026-04-13

Section 232 Pharma Tariffs 2026 | Trade Attorney California

How the April 2, 2026 Executive Order Imposing 100% Section 232 Tariffs on Patented Pharmaceuticals and APIs Threatens California's Biotech and Life Sciences Supply Chains

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

On April 2, 2026, President Trump signed an Executive Order imposing sweeping new Section 232 tariffs on imports of patented pharmaceuticals and active pharmaceutical ingredients (APIs), marking a dramatic escalation in trade policy that directly threatens the supply chains of California's vast biotech and pharmaceutical industry. The Secretary of Commerce determined that these imports threaten to impair U.S. national security under 19 U.S.C. § 1862, triggering tariff rates as high as 100 percen

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301